Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2006; 12(43): 6992-6997
Published online Nov 21, 2006. doi: 10.3748/wjg.v12.i43.6992
Published online Nov 21, 2006. doi: 10.3748/wjg.v12.i43.6992
Figure 1 Selection of patients according to the treatments given prior to LT.
Among a total of 105 HCC patients, 63 patients met the Milan criteria at the time of LT. After excluding 6 patients who received treatments other than TACE, there were 36 patients in TACE + LT group and 21 in LT group.
Figure 2 Representative cases for measurement of viable tumor size treated by TACE prior to LT.
A: A tumor nodule with compact lipiodol uptake, no enhancement at arterial phase, and no washout at portal or delayed phase was considered as a non-viable tumor and was excluded from the measurement of tumor size or number; B: For a nodule showing arterial enhancement and delayed washout at the margin, tumor size was defined as the difference from diameter of the entire nodule to diameter of lipiodol-uptaken portion.
Figure 3 Comparison of overall survival rate between TACE + LT and LT groups.
There was no obvious difference in 5-year survival rate after LT between the two groups (57% vs 74%; P = 0.70).
Figure 4 Comparison of cumulative HCC recurrence rate between TACE + LT and LT groups.
Five-year recurrence rate was similar between the two groups (8.3% vs 4.8%; P = 0.90).
- Citation: Kim DY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Shin SW, Choo SW, Do YS, Rhee JC. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol 2006; 12(43): 6992-6997
- URL: https://www.wjgnet.com/1007-9327/full/v12/i43/6992.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i43.6992